Disentangling mechanisms behind the pleiotropic effects of proximal 16p11.2 BP4-5 CNVs

3

4 5 Chiara Auwerx^{1,2,3,4,*}, Samuel Moix^{2,3,4}, Zoltán Kutalik^{2,3,4,*} & Alexandre Reymond^{1,*}

6 ¹ Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

7 ² Department of Computational Biology, University of Lausanne, Lausanne, Switzerland

8 ³ Swiss Institute of Bioinformatics, Lausanne, Switzerland

9 ⁴ University Center for Primary Care and Public Health, Lausanne, Switzerland

10 * Correspondence: chiara.auwerx@unil.ch; zoltan.kutalik@unil.ch; alexandre.reymond@unil.ch

11

12 Abstract

13 Whereas 16p11.2 BP4-5 copy-number variants (CNVs) represent one of the most pleiotropic 14 etiologies of genomic syndromes in both clinical and population cohorts, the mechanisms leading 15 to such pleiotropy remain understudied. Identifying 73 deletion and 89 duplication carriers among 16 unrelated white British UK Biobank participants, we performed a phenome-wide association study between the region's copy number and 117 complex traits and diseases, mimicking four dosage 17 18 models. Forty-six phenotypes (39%) were affected by 16p11.2 BP4-5 CNVs, with the deletion-19 only, mirror, U-shape, and duplication-only models being the best fit for thirty, ten, four, and two 20 phenotypes, respectively, aligning with the stronger deleteriousness of the deletion. Upon 21 individually adjusting CNV effects for either body mass index (BMI), height, cognitive function, or 22 socio-economic status as potential mediators, we found that sixteen testable deletion-driven 23 associations (61%) - primarily with cardiovascular and metabolic traits - were BMI-dependent, 24 with other mediators playing a more subtle role. Bidirectional Mendelian randomization supported 25 that 13 out of these 16 associations (81%) were secondary consequences of the CNV's impact 26 on BMI. For the 22 traits that remained significantly associated upon individual adjustment for 27 mediators, matched-control analyses found that eleven phenotypes, including musculoskeletal 28 traits, liver enzymes, fluid intelligence, platelet count, pulmonary capacity, pneumonia, and acute 29 kidney injury, remained associated under strict Bonferroni correction, with eight additional 30 nominally significant associations. These results paint a complex picture of 16p11.2 BP4-5's 31 pleiotropic pattern that involves direct effects on multiple physiological systems and indirect co-32 morbidities consequential to the CNV's impact on BMI and cognition, acting through trait-specific 33 dosage mechanisms.

34 Keywords

proximal 16p11.2 BP4-5 CNV; structural variants; genomic disorder; PheWAS; multi-system
disorder; pleiotropy; mediation; obesity.

37

38 **Abbreviations**

39 ALP = alkaline phosphatase; ALT = alanine aminotransferase; AKI = acute kidney injury; AST = 40 aspartate aminotransferase; **BMI** = body mass index; **BP** = breakpoint; **CI** = confidence interval; 41 **CKD** = chronic kidney disease; **CNV** = copy-number variants; **COPD** = chronic obstructive pulmonary disorder; **CRP** = C-reactive protein; **EA** = educational attainment; **FVC** = forced vital 42 43 capacity; GGT = gamma-glutamyltransferase; GWAS = genome-wide association studies; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; HTN = essential hypertension; ICD-10 = 44 International Classification of Diseases, 10th Revision; **IGF-1** = insulin-like growth factor 1; **kb** = 45 46 kilobase pair; **MR** = Mendelian randomization; **OA** = arthritis; **PheWAS** = phenome-wide 47 association study; SE = standard error; SES = socioeconomic status; SHBG = sex hormone binding globulin; **SNP** = single nucleotide polymorphism; **T1D** = type 1 diabetes; **TDI** = Townsend 48 49 deprivation index; UKBB = UK Biobank; WHR = waist-to-hip ratio; WHRadjBMI = WHR adjusted for BMI. 50

51 Introduction

52 Genomic disorders are caused by recurrent genomic rearrangements that lead to the gain 53 (duplication) or loss (deletion) of large, multi-kilobase pair (kb) DNA fragments. The proximal 54 16p11.2 rearrangement spans a region of ~600 kb between recurrent breakpoints (BP) 4 and 5 and includes 27 unique protein-coding genes. Copy-number variants (CNVs) of the region 55 56 represent one of the most common genomic disorders, with population prevalence estimates of 57 1 in 3,000 and 1 in 2,800 for the deletion (MIM: 611913) and duplication (MIM: 614671), 58 respectively (in litt.). Prevalence in clinical cohorts is about eight-fold higher, with a particularly 59 strong enrichment in individuals ascertained for intellectual disability and developmental delay¹⁻³ or autism spectrum disorder⁴⁻⁷, the first phenotypes associated with the CNV. Other hallmark 60 features include a negative dosage effect on body mass index (BMI)⁸⁻¹⁰ and head 61 circumference^{11,12}, a predisposition for seizure disorders^{2,3,11,13}, and a duplication-specific 62 increased susceptibility to schizophrenia and other psychiatric conditions^{12,14–19}. The recent 63 64 establishment of large biobanks coupling genetic information to phenotypic data such as physical 65 measurements, blood biomarkers, and electronic health records, has allowed to study the 66 phenotypic expression of 16p11.2 BP4-5 rearrangements in individuals that are typically older and less severely affected than those recruited in pediatric clinical cohorts²⁰⁻³¹. Results of these 67 68 studies often converge onto similar pathophysiological processes than those highlighted by 69 clinical studies but also report associations with biomarkers and common diseases that are 70 typically overlooked or not assessed in clinical cohorts.

71

72 If the pleiotropic nature of 16p11.2 BP4-5 rearrangements is now well-established, the 73 mechanisms through which CNVs in the region affect such diversity of traits remain poorly studied. 74 Under a model of direct (or horizontal) pleiotropy, the CNV causally impacts associated 75 phenotypes through independent mechanisms (Figure 1A). Conversely, indirect (or vertical) 76 pleiotropy implies that the CNV causally impacts a mediatory trait, which in turn causally impacts 77 other traits that will appear as linked with the CNV in association studies (Figure 1B). These 78 models are not mutually exclusive, and a fraction of the associations might result from direct 79 effects while others might be secondary consequences. This question is particularly relevant given the BMI-modulating role of the 16p11.2 BP4-5 CNV^{8-10,20,21,24,25} – which itself represents a 80 81 strong risk factor for other diseases - and could therefore inform epidemiology of associated 82 comorbidities and clinical practice. To address this knowledge gap, we re-analyzed two recent UK 83 Biobank (UKBB) studies that assessed the impact of 16p11.2 BP4-5 rearrangements on 117

complex traits and common diseases^{21,22} with the aims to i) determine the most likely dosage mechanism for different traits and ii) estimate the fraction and nature of associations that are mediated by primary changes in anthropometric measurements, cognitive ability, and socioeconomic status (Figure 1C).



Figure 1. Study workflow.

(**A**-**B**) Schematic representation of pleiotropy mechanisms. For illustration, the 16p11.2 BP4-5 deletion is depicted but the same concept applies to the duplication. (A) Direct (horizontal) pleiotropy: The CNV causally affects multiple traits – here Trait₁, Trait₂, and Trait₃ – through independent mechanisms. (B) Indirect (vertical) pleiotropy: The CNV causally impacts Trait₁, which in turn causally affects Trait₁ and Trait₃. The impact of the deletion on Trait₁ and Trait₃ is thus indirect and mediated by a shared mechanism, i.e., Trait₂. (**C**) Overview of the study. The first two analyses aim at detecting and characterizing the pleiotropy of 16p11.2 BP4-5 CNVs through four distinct dosage models that estimate the effect of the CNV on the trait (Y) either (1) without or (2) with adjustment for one of four covariates that could potentially mediate the CNV-phenotype association. The second part of the study aims at understanding the causal relationship between trait-mediator pairs for which the significance of the CNV effect on the trait was affected by adjustment for the mediator. Support for mediation was claimed when the forward MR effect of the mediator on the trait ($\alpha_{M \to T}$) is significant and larger than the reverse effect of the trait on the mediator ($\alpha_{T \to M}$), providing the latter is significant. (4) For traits that showed a significant association with the CNV regardless of covariate adjustment, we performed a matched-control analysis that allowed us to adjust for all possible mediators simultaneously and detect likely genuine, direct pleiotropic associations. PheWAS = phenome-wide association study.

88 Materials and methods

- 89 1. Study material
- 90 Software versions
- 91 Statistical analyses and graphs were generated with R v4.3.1. The Mendelian randomization
- 92 analysis pipeline uses the TwoSampleMR R package v0.5.7³² and PLINK v1.9³³ and was
- 93 implemented in R v4.2.1.
- 94

95 Cohort description & sample selection

96 Analyses were carried out in the UKBB, a volunteer-based UK population cohort of about half a 97 million individuals (54% females) aged 40-69 years at recruitment, who signed a broad informed consent form³⁴. Available data include microarray genotype data acquired in GRCh37/hg19 from 98 99 two similar arrays, as well as rich phenotypic data, including anthropometric measurements, vital signs, blood biomarker levels, life history and lifestyle questionnaire data, hospital-based 100 International Classification of Diseases, 10th Revision (ICD-10) codes (up to September 2021), 101 and self-reported conditions. Analyses conducted in this study focus on 331,522 unrelated 102 103 individuals from the "white British" UKBB subset (54% females) that were filtered to exclude 104 samples with abnormal CNV profiles and/or a report of blood malignancy. Filtering criteria to obtain this set are described elsewhere²². 105

106

107 CNV carrier identification

CNV calls from a previous study were used²¹. Briefly, CNV calling was done based on the UKBB 108 microarray data using standard PennCNV v1.0.5 settings³⁵. Each call was attributed a quality 109 110 score ranging from -1 (likely deletion) to 1 (likely duplication) reflecting the probability for the CNV 111 to be a consensus call across three algorithms and thus a true positive³⁶. 16p11.2 BP4-5 deletion 112 and duplication carriers were identified as carrying a high-confidence CNV call (quality score < -113 0.5 for deletions; guality score > 0.5 for duplications) on chromosome 16 with start and end site 114 within 29.4-29.8 Mb and 30.05-30.4 Mb, respectively. Individuals with a low-quality 16p11.2 BP4-115 5 CNV were excluded from copy-neutral controls. CNV genotype vectors were then encoded to 116 allow the fitting of regression models according to four dosage mechanisms (Table 1).

Table 1. Encoding of CNV carrier status for different dosage models.

Numerical encoding of CNV genotypes for high confidence deletion carriers, copy-neutral individuals, and high confidence duplication carriers according to four dosage mechanisms of action. Individuals with a low-quality score CNV call are set as missing.

	deletion (copy-number = 1)	copy-neutral (copy-number = 2)	duplication (copy-number = 3)	
mirror	-1	0	1	
U-shape	1	0	1	
duplication-only	NA	0	1	
deletion-only	1	0	NA	

117 Phenotype selection

118 We analyzed the same 117 phenotypes as defined in previous studies^{21,22}. This includes 57

119 quantitative traits²¹ that were inverse normal transformed before being corrected for sex (except

120 for sex-specific traits), age (UKBB field identifier #21003), age², genotyping batch, and principal

121 components 1-40. We further include 60 common diseases based on ICD-10 clinical diagnoses
 122 using a case-control definition procedure that excludes from controls individuals with a condition

123 124

125 *Mediator selection*

related to the one under investigation²².

We tested the role of four factors that could potentially mediate associations between 16p11.2BP4-5 CNVs and the assessed phenotypes:

- Body mass index (BMI): average over available instances of BMI (#21001).
- Educational attainment (EA): age at which full-time education was completed (#845).
 Values matching "prefer not to answer", "never went to school", and "do not know" were
 set as missing, and average over available instances was calculated. Individuals for which
 average age at which full-time education was completed was below 14 years or over 19
 years were set to 14 years and 19 years, respectively. Individuals reporting a "college or
 university degree" in their qualifications (#6138) were set to 19 years.
- Townsend deprivation index at recruitment (TDI; #22189).
- Height: average over available instances of standing height (#50).
- 137

138 *GWAS summary statistics*

139 Mendelian randomization (MR) studies rely on publicly available genome-wide association 140 studies (GWASs) summary statistics for both sexes and individuals of European ancestry. For 141 mediators, summary statistics from Pan-UK Biobank with phenotype manifest updated on 01/03/2023 (https://pan.ukbb.broadinstitute.org/)³⁷ were used for BMI. TDI. and height. For EA. 142 143 summary statistics from a large meta-analysis were used (excluding 23andMe data; http://www.thessgac.org/data)³⁸. For other phenotypes, summary statistics from the Neale group 144 145 released on 07/2018 were used (http://www.nealelab.is/uk-biobank). These summary statistics 146 were favored over those of large disease-specific consortia as summary statistics for binary traits 147 were calculated through linear regression, allowing comparison of forward and reverse effects. 148 For diseases, we used the closest possible match to our phenotype definition, i.e., phenotype 149 code: E10 for "T1D" (type 1 diabetes); G47 for "sleep" (sleep apnea); I10 for "HTN essential" 150 (essential hypertension); I35 for "valves" (cardiac valve disorders); I44 for "conduction" (cardiac conduction disorders); J45 for "asthma"; M19 for "OA" (arthrosis); N18 for "CKD" (chronic kidney 151 152 disease); 20002 1473 for "lipid" (lipidemias & lipoprotein disorders). Summary statistics for 153 autosomal chromosomes were harmonized to the UK10K reference panel³⁹. After excluding

- palindromic single-nucleotide polymorphisms (SNPs) and adjusting strand-flipped SNPs, effect
 sizes were standardized to represent the square root of the explained variance.
- 156

157 2. 16p11.2 BP4-5 association studies

158 *Phenome-wide association study*

159 For the phenome-wide association study (PheWAS), regression analysis was performed to 160 estimate the effect of the CNV genotype – encoded according to either of the four models in Table 161 1 - and the 117 selected phenotypes. For quantitative traits, linear regressions (lm() in R) were 162 used and 95% confidence intervals (CI) were calculated as beta ± 1.96*standard error (SE). For 163 binary traits, Firth's bias-reduced penalized-likelihood logistic regression was used 164 (logistf(plconf = 2, maxit = 100, maxstep = 10) from the logistf package 165 v1.26.0 in R) to account for the fact that both CNV carriers and disease cases are rare. The same 166 function also produces estimates for the 95% CIs. As disease diagnoses were defined as binary variables and could not be adjusted beforehand, sex (except for sex-specific traits), age, 167 168 genotyping array, and principal components 1-40 were included as covariates. For each trait, the 169 dosage model yielding the lowest p-value for the CNV effect was retained and effects were defined as strictly significant under Bonferroni correction criteria ($p \le 0.05/117 = 4.3 \times 10^{-4}$). 170

171

172 Covariate analysis

173 For all phenotype-mediator pairs (*Phenotype & Mediator selection*), including those involving 174 phenotypes that did not significantly associate with the CNV status in our original PheWAS, we 175 estimated the Pearson correlation (cor (use = "pairwise.complete.obs") in R), as well 176 as the effect of the mediator on the phenotype in a linear/Firth regression model without 177 covariates, as previously described (*Phenome-wide association study*). For pairs with Pearson correlation < 0.5 and effect of the mediator on the trait $p \le 0.05/117 = 4.3 \times 10^{-4}$, we estimated the 178 179 effect of the CNV carrier status encoded according to the best PheWAS model. Regressions were 180 implemented as previously described (*Phenome-wide association study*), adding the mediator as 181 an additional covariate. Adjusted effects were defined as strictly significant when meeting 182 Bonferroni correction criteria ($p \le 0.05/117 = 4.3 \times 10^{-4}$). We additionally compared effect 183 estimates with $(\beta_{adjusted})$ and without (β) mediator adjustment based on a t-statistic

$$t = \frac{\beta - \beta_{adjusted}}{\sqrt{SE^2 + SE_{adjusted}^2}}$$

where SEs represent the standard errors of the effects. Two-sided p-values were calculated
 (2*pnorm(-abs(t), mean = 0, sd = 1) in R). The difference in correlation between BMI dependent and BMI-independent traits with BMI was assessed with a two-sided t-test.

187

188 Mendelian randomization

189 GWAS summary statistics were used to conduct bidirectional MR according to a previously published pipeline^{40,41} for 31 mediator-trait pairs for which the CNV-trait association either gained 190 191 or lost significance upon adjusting for that mediator. Concretely, the forward effect of the mediator 192 (exposure) on the trait (outcome) and the reverse effect of the trait (exposure) on the mediator (outcome) were estimated. Harmonized SNPs significantly ($p < 5 \times 10^{-8}$) associating with the 193 194 exposure were clumped with PLINK v1.9 (p1 = 0.0001, p2 = 0.01, kb = 250, and r2 195 = 0.01) and retained as instrumental variables. Instrumental variables mapping to the extended 196 HLA region (chr6:25,000,000-37,000,000; GRCh37/hg19) were excluded, as well as those with 197 a difference in allele frequency (≥ 0.05) between the outcome and exposure summary statistic. 198 Steiger filtering was applied ($Z \le -1.96$) to ensure that the effect of the selected variants on the 199 exposure was stronger than their effect on the outcome. Bidirectional inverse variance weighted 200 MR analyses were carried out with the TwoSampleMR R package when at least two instrumental 201 variables were available. MR effects were called significant under Bonferroni correction, when p $\leq 0.05/62 = 8.1 \times 10^{-4}$, to account for the 31 bidirectional tests performed. 202

203

204 Matched-control analysis

205 For each CNV carrier, we identified all copy-neutral unrelated individuals from the "white British" 206 subset of UKBB participants that were matching based on sex (identical), age (± 2.5 years), BMI 207 (± 2.5 years), TDI (± 2), average household income before tax (#738) averaged over instances 208 (identical category), and EA (± 1 year). Fifty-eight deletion and sixty-one duplication carriers had 209 no missing data and gualified for the matching procedure. The number of identified matching 210 controls per carrier ranged from 1 to 918 and 12 to 1,590 for deletion and duplication carriers, 211 respectively, with 49 deletion and 60 duplication carriers having at least 25 matching controls. 212 When more than 25 matched controls were available, the ones used for the analysis were 213 selected randomly (sample n() in R), without replacement. For quantitative traits, we compared 214 mean phenotypic values between deletion and duplication carriers and the respective control 215 groups through a two-sided t-test. For binary traits, disease prevalence was compared between 216 the same groups based on a two-sided Fisher test. Prevalence standard error was calculated as 217

$$SE = \sqrt{\frac{q * (1 - q)}{n}}$$

where *q* is the disease prevalence, and *n* the sample size. Sample sizes vary between phenotypes due to missing data. We define significant associations based on a Bonferroni correction that accounts for the 22 traits of interest in this analysis ($p \le 0.05/22 = 2.3 \times 10^{-3}$), i.e., phenotypes that remained associated with the CNV under strict Bonferroni correction when adjusting for BMI, height, EA, or TDI individually. We report all nominally significant (p < 0.05) associations on figures.

224

In a related analysis aiming at assessing the consequences of losing samples for the matched-

control analysis, we used the same statistical framework to compare mean phenotypic value and

227 disease prevalence between deletion and duplication carriers that were included in the matched-

- control analysis versus those that were not due to missing data or lack of sufficient controls.
- 229

230 **Results**

Using previously published high confidence CNV calls for 331,522 unrelated, white British UKBB 231 participants^{21,22}, we identified 73 and 89 individuals with a 16p11.2 BP4-5 (start: chr16:29.40-232 233 29.80 Mb; end: chr16:30.05-30.40 Mb) deletion and duplication, respectively. CNV genotypes 234 were encoded to allow testing of four dosage mechanisms, namely a mirror model assessing the 235 additive impact of each additional copy, a U-shape model testing the same-direction impact of 236 any deviation from the copy-neutral state, and duplication- and deletion-only models that assess 237 the separate impact of duplications and deletions, respectively. Next, we evaluated the 238 association between an individual's CNV carrier status and 117 phenotypes - that comprise 57 239 quantitative variables including anthropometric measurements, vital signs, biomarker levels, life history events, and 60 common diseases – while correcting for sex, age, age², genotyping array, 240 241 and population stratification (Figure 2: Table S1).

Table 2. Traits significantly associated with 16p11.2 BP4-5 CNVs.

Traits that are significantly ($p \le 0.05/117 = 4.3 \times 10^{-4}$) associated with 16p11.2 BP4-5 CNVs through at least one of the four assessed association models, following the ordering of Figure 2. (**A**) For quantitative traits, the mean value of the traits in copy-neutral individuals (controls) is provided along with the mean value and standard error (SE) among duplication and deletion carriers. The number of duplication and deletion carriers with available data is specified as N. Values are given in the indicated unit. (**B**) For binary disease traits, prevalence in percentage among copy-neutral individuals is provided along with prevalence and SE among duplication and deletion carriers. Diseased (case) and total (N) number of duplication and deletion carriers are indicated.

CNV status		controls	deletion carriers		duplication carriers			
A. Quantitative traits								
	unit	mean	N	mean ± SE	N	mean ± SE		
fluid intelligence score	points	6.24	26	5.15 ± 0.39	32	4.05 ± 0.37		
platelet count	10 ⁹ cells/L	252.8	70	286.4 ± 7.5	85	219.4 ± 5.7		
neutrophil count	10 ⁹ cells/L	4.25	70	5.00 ± 0.15	85	4.14 ± 0.15		
heel bone mineral density	g/cm ²	0.54	29	0.66 ± 0.04	47	0.46 ± 0.01		
height	cm	168.8	73	163.3 ± 1.0	89	171.1 ± 1.1		
insulin-like growth factor 1 (IGF-1)	nmol/L	21.4	71	18.9 ± 0.7	88	21.4 ± 0.6		
hand grip strength	kg	30.7	73	26.7 ± 1.0	89	28.6 ± 1.2		
vitamin D	nmol/L	49.8	68	36.0 ± 2.1	86	44.7 ± 2.2		
forced vital capacity (FVC)	L	3.63	64	2.94 ± 0.11	72	3.64 ± 0.12		
pulse rate	bpm	69.3	67	74.3 ± 1.5	81	71.3 ± 1.3		
body mass index (BMI)	kg/m ²	27.4	72	35.0 ± 0.9	89	26.3 ± 0.4		
whole body fat mass	kg	24.9	67	35.5 ± 1.6	85	23.2 ± 0.9		
glycated hemoglobin (HbA1c)	mmol/mol	36.0	70	43.3 ± 1.8	85	35.7 ± 0.5		
waist-to-hip ratio (WHR)	-	0.87	72	0.97 ± 0.01	89	0.87 ± 0.01		
C-reactive protein (CRP)	m/L	2.57	71	5.50 ± 0.76	88	2.03 ± 0.23		
weight	kg	78.3	72	93.3 ± 2.7	89	77.1 ± 1.4		
triglycerides	mmol/L	1.75	71	2.30 ± 0.14	87	1.60 ± 0.09		
HDL cholesterol	mmol/L	1.46	61	1.26 ± 0.04	79	1.45 ± 0.04		
WHR adjusted for BMI	-	0.00	71	0.03 ± 0.01	89	0.01 ± 0.01		
gamma-glutamyltransferase (GGT)	U/L	37.3	71	64.1 ± 11.3	87	27.7 ± 2.8		
alkaline phosphatase (ALP)	U/L	83.6	71	99.8 ± 3.4	88	79.8 ± 2.6		
aspartate aminotransferase (AST)	U/L	26.2	70	35.8 ± 6.7	87	23.4 ± 0.7		
alanine aminotransferase (ALT)	U/L	23.5	71	31.2 ± 2.1	88	20.8 ± 1.3		
albumin	g/L	45.3	61	44.0 ± 0.4	79	45.6 ± 0.3		
cystatin C	mg/L	0.91	71	1.04 ± 0.02	88	0.93 ± 0.02		
creatinine	μmol/L	72.4	71	68.8 ± 1.6	87	76.9 ± 2.0		
urate	μmol/L	309.4	70	355.2 ± 8.1	88	298.8 ± 9.1		
age at menarche	years	12.9	27	11.7 ± 0.3	45	14.0 ± 0.4		
relative age at first facial hair (group 1-3)	-	2.06	41	1.83 ± 0.06	38	2.26 ± 0.08		
sex hormone binding globulin (SHBG)	nmol/L	51.9	61	38.4 ± 2.4	77	58.8 ± 3.4		
B. Disease Prevalence								
		prevalence	case/N	prevalence ± SE	case/N	prevalence ± SE		
sleep apnea		2.1%	9/60	15.0 ± 4.6%	0/70	0.0 ± 0.0%		
recurrent depressive disorder		0.3%	0/49	0.0 ± 0.0%	3/68	4.4 ± 2.5%		
bipolar affective disorder		0.4%	1/50	2.0 ± 2.0%	6/71	8.5 ± 3.3%		
schizophrenia		0.2%	2/51	3.9 ± 2.7%	3/68	4.4 ± 2.5%		
other anemias		5.5%	13/67	19.4 ± 4.8%	6/84	7.1 ± 2.8%		
arthrosis (OA)		21.1%	23/62	37.1 ± 6.1%	15/74	20.3 ± 4.7%		
pneumonia		5.9%	19/61	31.1 ± 5.9%	2/83	2.4 ± 1.7%		
chronic obstructive pulmonary disease (COPD)		4.9%	17/55	30.9 ± 6.2%	4/76	5.3 ± 2.6%		
asthma		12.1%	19/55	34.5 ± 6.4%	9/69	13.0 ± 4.1%		
cardiac valve disorders		5.0%	7/33	21.2 ± 7.1%	3/54	5.6 ± 3.1%		
cardiac conduction disorders		19.5%	18/44	40.9 ± 7.4%	13/64	20.3 ± 5%		
essential hypertension (HTN)		35.3%	36/62	58.1 ± 6.3%	23/74	31.1 ± 5.4%		
type 1 diabetes (T1D)		1.0%	4/42	9.5 ± 4.5%	1/75	1.3 ± 1.3%		
lipidemias & lipoprotein disorders		22.0%	23/48	47.9 ± 7.2%	11/57	19.3 ± 5.2%		
acute kidney injury (AKI)		4.7%	20/65	30.8 ± 5.7%	7/71	9.9 ± 3.5%		
chronic kidney disease (CKD)		4.4%	9/54	16.7 ± 5.1%	6/70	8.6 ± 3.3%		



Figure 2. 16p11.2 BP4-5 phenome-wide association study.

Effect sizes (beta; x-axis) with 95% confidence interval (CI) of the 16p11.2 BP4-5 deletion (circle) and duplication (square) on 117 complex traits and diseases, ordered by physiological system (y-axis). Effect sizes are in standard deviation units of the outcome (quantitative traits) or logarithms of the odds ratio of a logistic regression (disease traits). Deletion- and duplication-only effects that are significant under Bonferroni correction ($p \le 0.05/117 = 4.3 \times 10^{-4}$) are in blue and red, respectively, while non-significant effects are in grey. If the most significant among the four tested association models was the mirror or U-shape model, it is denoted with an "M" or "U", respectively (right).

242 Overall, 46 (39%) traits, including 16 diseases, were associated with the CNV carrier status under at least one association model (Bonferroni correction: $p \le 0.05/117 = 4.3 \times 10^{-4}$; Table 2), with an 243 244 additional 32 (27%) showing a trend for association (nominal significance: $p \le 0.05$). Specifically, 245 10 and 38 traits showed a significant association through the duplication-only and deletion-only 246 models, respectively, indicating a stronger propensity for pleiotropy and deleteriousness of the 247 deletion, compared to the duplication. Exceptions are recurrent depression and bipolar disorder, the two only traits for which the duplication-only model yielded the most significant result. This is 248 in line with the duplication representing a strong susceptibility factor for psychiatric conditions^{12,14–} 249 250 ¹⁹. Similarly, the risk for schizophrenia was strongly increased by the duplication, even if our 251 analysis finds that the relation is better described by a U-shape model wherein the deletion also 252 tends to increase schizophrenia risk. Surprisingly, the CNV did not associate with neuroticism

score, despite the high genetic correlation between neuroticism and psychiatric conditions⁴². 253 254 Three other traits, namely fluid intelligence, vitamin D, and waist-to-hip ratio adjusted for BMI 255 (WHRadjBMI), were also most significantly associated through a U-shape effect, while grip 256 strength was decreased in both deletion and duplication carriers, but more strongly in the former. 257 Conversely, ten traits were most significantly associated through a mirror model, including multiple 258 hepatic biomarkers, platelet count, and traits related to sexual characteristics such as puberty 259 timing and sex hormone binding globulin (SHBG) levels. Finally, the deletion-only model was the 260 most significant fit for 30 phenotypes, including mostly pulmonary, cardiovascular, metabolic, and 261 renal traits.

262

263 Having characterized the pleiotropic nature of 16p11.2 BP4-5 rearrangements, we next sought to 264 establish whether some of these associations might be secondary to the CNV affecting core 265 mediatory phenotypes, i.e., reflect indirect pleiotropy (Figure 1B). We focus on four traits that 266 proxy hallmark features of the 16p11.2 BP4-5 rearrangement and have the potential to influence 267 other associated traits: i) BMI, which characterizes the negative correlation between dosage and adiposity^{8–10,20,21,24,25} and represents a major risk factor for many common diseases; ii) Height, 268 which is reduced in deletion carriers^{16,20,21,24,36} and can influence musculoskeletal phenotypes; iii) 269 270 Educational attainment (EA) proxied by age at which an individual completed their education. This 271 variable offers the advantage of being available for the near totality of the UKBB cohort while 272 strongly correlating with fluid intelligence score that is limited to about half of its participants 273 (Pearson correlation = 0.42), thereby reflecting the decreased cognitive function observed in both duplication and deletion carriers^{2,3,16,17,21,31,43}; and iv) Townsend deprivation index (TDI) as a 274 275 measure of socio-economic status (SES), which we expect to be reduced as a corollary of the 276 health burden imposed by the CNV²⁰. Of note, while TDI specifically aims at assessing SES, BMI, 277 height, and EA also partly capture SES⁴⁴. For the association between CNV and phenotype to be mediated by one of these factors, the mediator needs to significantly ($p \le 0.05/117 = 4.3 \times 10^{-4}$) 278 279 associate with the tested phenotype. Furthermore, phenotypes cannot be too correlated with the 280 mediator (Pearson's correlation > 0.5), as in such situations distinguishing mediator and outcome 281 would be particularly difficult. For all mediator-trait pairs that fulfilled these criteria, we tested the 282 impact of adjusting the CNV-trait effect for mediatory factors by including them individually in the 283 regression model yielding the most significant CNV-trait effect (Figure 3A; Table S2).



Figure 3. Mediation of 16p11.2 BP4-5 pleiotropy through anthropometric traits and socio-economic factors. (A) Effects (beta) of 16p11.2 BP4-5 CNVs on traits with adjustment for potential mediators (y-axis) – i.e., body mass

(A) Effects (beta) of hop 11.2 bF4-5 CrVvs of traits with adjustment for potential mediators (y-axis) – i.e., body mass index (BMI), Townsend deprivation index (TDI), age at end of education (EA), and height (rows, right) – against those without adjustment (x-axis), stratified (columns, top) according to the best (i.e., most significant) association model (shape). Only associations that were significant prior to or become significant after adjustment are plotted. Traits are colored according to physiological system. Size reflects whether the effect is Bonferroni significant after adjusting for the potential mediator (large) or not (small). Traits losing significance upon adjustment are labeled. Grey dashed diagonal represents the identity line. (B) Enlargement of the area delimited by a red dashed rectangle in (A), showing the effect of BMI adjustment for deletion-driven association, using the same legend as in (A). (C) Schematic of the links between copy-number variant (CNV), potential mediators, and assessed traits. Covariate-adjusted phenome-wide association studies (PheWAS) identified CNV-trait associations that are dependent on either of the four tested factors (thick grey arrow) in (A). This scenario can be through mediation, collider bias, or confounding. We used Mendelian randomization (MR) to assess the genetically determined causal effect of the putative mediator on the trait (forward effect, red arrow) and of the trait on the mediator (reverse effect; dark blue arrow). MR effect arrows are proportional to

causal effect sizes. When the forward effect is larger than the reverse one, mediation is a likely scenario; when the reverse effect is larger, the putative mediator likely acts as a collider; absence of causal effects likely indicates presence of an unobserved confounder, U. Depending on the scenario, adjustment for the mediator in the regression analysis might (green) or might not (red) be appropriate, as reflected by the color of each scenario's title. (**D**) Bidirectional forward (red) and reverse (dark blue) MR effects with 95% confidence interval (CI; x-axis truncated on the right) of potential mediators (left y-axis) on traits (right y-axis) for all mediator-trait pairs that either gained or lost significance upon adjustment for the mediator. Non-significant effects ($p > 0.05/62 = 8.1 \times 10^{-4}$) are semi-transparent. ALT = alanine aminotransferase; CKD = chronic kidney disease; CRP = C-reactive protein; HDL = high-density lipoprotein cholesterol; HTN = essential hypertension; IGF-1 = insulin-like growth factor 1; OA = arthritis; SHBG = sex hormone binding globulin; T1D = type 1 diabetes; TG = triglycerides; WHRadjBMI = waist-to-hip ratio adjusted for BMI.

284 Upon adjustment for BMI, TDI, EA, and height, nineteen, four, four, and zero CNV-trait 285 associations fell below the significance cutoff ($p \le 0.05/117 = 4.3 \times 10^{-4}$), respectively. Comparing effect sizes. only the mirror association with sleep apnea was nominally significantly reduced upon 286 287 adjustment for BMI (p = 0.04). Remarkably, the association with basal metabolic rate (deletion-288 only) became significant upon adjustment for height, while the one with diastolic blood pressure 289 (mirror), eosinophil count (deletion-only), and lymphocyte count (deletion-only) became so upon 290 adjustment for BMI (Figure S1A), even though the change in effect size were not significant (p > 291 0.45). The impact of adjusting for BMI was most striking on deletion-driven associations, for which 292 61% (16/26) of the associations fell below the significance threshold (Figure 3B). In line with 293 expectations, BMI-dependent traits tended to have a stronger correlation with BMI than those that 294 remained significant upon adjustment for BMI (p = 0.05) (Figure S1B). Among the lost 295 associations, we find nine out of the ten metabolic and cardiovascular traits associated with the 296 deletion. These associations likely reflect secondary consequences of the propensity for obesity 297 of deletion carriers as they include levels of serum lipid and the inflammation biomarker C-reactive 298 protein (CRP), cardiac valve and conduction disorders, and hypertension. The effect of BMI on 299 musculoskeletal, pulmonary, or renal traits is more balanced, with some associations, such as the 300 ones with arthritis (OA), asthma, or urate and chronic kidney disease (CKD), appearing to be 301 driven by BMI, while others, such as grip strength, chronic obstructive pulmonary disease 302 (COPD), or cystatin C and acute kidney injury (AKI), remaining significant upon BMI adjustment. 303 The mediating role of TDI and EA was much milder, as only four associations were lost upon 304 adjustment for either variable – including a shared association with WHR adjusted for BMI, heart 305 rate, and high-density lipoprotein (HDL) cholesterol – suggesting that TDI and EA capture partially 306 overlapping mediatory processes. Surprisingly, associations with psychiatric disorders were not 307 affected by EA, suggesting that cognition and psychiatric diseases are regulated by (at least 308 partially) independent pathways. Finally, the observation that no associations were affected by 309 adjusting for height confirms that the decrease in traits such as grip strength and forced vital 310 capacity among deletion carriers is not driven solely by their short stature.

311

312 One caveat of our analysis is that it cannot distinguish whether changes in CNV-trait associations 313 are indeed secondary effects of the mediator on the trait. At least three scenarios could result in 314 the loss (or gain) of a CNV-trait effect upon covariate adjustment (Figure 3C). The first one is 315 mediation, wherein the CNV affects the trait through the mediator, resulting in a dominant causal 316 effect of the mediator on the trait. The second scenario is when the variable we adjusted for turns 317 out to be a collider of the CNV and the trait, in which case we expect a dominant causal effect 318 from the trait to the "mediator". Finally, data could be explained by an unobserved confounder that 319 affects both the adjustment variable and the trait, in which case we do not expect any causal link 320 between trait and mediator. Of note, in the latter scenario, we further distinguish between whether 321 the CNV has an impact on the confounder, the "mediator", the trait, or a combination thereof. 322 Importantly, adjusting for the mediator in the regression model is an appropriate solution to obtain 323 meaningful direct CNV-trait effects (i.e., genuine direct pleiotropy) only in the i) mediator scenario 324 or ii) the confounder scenario where the CNV has a direct effect on the trait, in which case adjustment for the mediator could result in a gain of power (Figure 3C). To identify cases where 325 326 mediation is a likely scenario, we resorted to bidirectional Mendelian randomization (MR), a 327 causal inference approach that allows to estimate the genetically determined causal effect of an 328 exposure on an outcome (Figure 3D; Table S3). Firstly, we estimated the forward mediator-to-trait 329 effect for all 31 mediator-trait pairs that either gained (N = 4; Figure S1A) or lost (N = 27; Figure 330 3A-B) significance upon adjustment for the mediator. Except for the four TDI-dependent 331 associations which had large confidence intervals due to the lack of good genetic instruments for 332 TDI and the effect of BMI on hypertension, type 1 diabetes, and cardiac conduction disorders, all effects were significant ($p \le 0.05/62 = 8.1 \times 10^{-4}$), confirming that the mediators can causally 333 334 influence the involved traits. Secondly, we estimated the reverse trait-to-mediator causal effects. 335 Ten reverse effects were significant and thus represent mediator-trait pairs at risk for collider bias. 336 Yet, for nine of them, the forward effect had a larger magnitude, making the mediator-to-trait 337 causal path more likely. The only exception is the association between the deletion and basal 338 metabolic rate that became significant upon adjustment for height and for which the reverse effect 339 was stronger than the forward effect. This suggests that height could act as a collider and 340 adjustment for it could bias estimates. Hence, we conclude based on the unadjusted effect that 341 the association between the deletion and basal metabolic rate is non-significant. It is also worth 342 noting that six out of seven associations lacking a significant forward effect also lacked a 343 significant reverse effect, possibly indicating presence of an unobserved confounder. This is 344 particularly likely for the BMI effect on hypertension, type 1 diabetes, and cardiac conduction

disorders, where estimates are close to null despite being well-instrumented (≥ 50 instruments).
Globally, these analyses support that a large fraction (74%) of the flagged associations are likely

- 347 indirect consequences of the CNV's effect on our selected mediators.
- 348

349 Next, we focused on the 22 traits whose association with the CNV remained significant after 350 adjusting for BMI, height, TDI, or EA. To confirm that these represent cases of genuine direct 351 pleiotropy, we used a matched-control approach that offers the advantage of allowing adjustment 352 for multiple mediatory variables at once but at the cost of losing some statistical power. 353 Specifically, for each of the 58 deletion and 61 duplication carriers with sufficient data to carry out 354 the matching, we identified individuals with matched age (± 2.5 years), sex (identical), BMI (± 2.5 355 kg/m²), TDI (± 2), income class (identical), and EA (± 1 year) among a pool of copy-neutral, 356 unrelated, white British UKBB participants (Figure S2). For 49 deletion and 60 duplication carriers, 357 at least 25 matched controls could be identified, and phenotype mean or disease prevalence 358 between the two CNV groups and their respective controls were compared (Figure 4; Tables S4-5). Eleven traits (50%) retained a strictly significant effect ($p \le 0.05/22 = 2.3 \times 10^{-3}$), affecting six 359 360 independent physiological systems: musculoskeletal, neuropsychiatric, pulmonary/immune, 361 renal, hepatic, and hematological. Specifically, deletion carriers presented with decreased hand grip strength ($p = 1.4 \times 10^{-3}$; Figure 4A), shorter stature ($p = 1.2 \times 10^{-5}$; Figure 4B), increased 362 alkaline phosphatase (ALP; $p = 1.8 \times 10^{-3}$; Figure 4G), decreased forced vital capacity (FVC; p =363 364 2.2 x 10⁻³; Figure 4R), and increased risk for pneumonia ($p = 3.8 \times 10^{-4}$; Figure 4Q) and AKI (p =2.9 x 10⁻⁴; Figure 4T). Duplication carriers showed decreased bone mineral density ($p = 6.3 \times 10^{-1}$ 365 366 ⁴; Figure 4C), lower aspartate aminotransferase (AST; $p = 1.5 \times 10^{-3}$; Figure 4E) and gammaglutamyltransferase (GGT; $p = 2.2 \times 10^{-4}$; Figure 4F) levels, and reduced fluid intelligence (p = 1.6367 x 10⁻³; Figure 41). Noteworthy is the strong mirror effect on platelet count (Figure 4P), with higher 368 369 $(p = 1.9 \times 10^{-3})$ and lower $(p = 3.4 \times 10^{-4})$ counts observed in deletion and duplication carriers, 370 respectively. Whereas for the other phenotypes the other CNV type did not meet the strict 371 significance criteria, all effects, showed a trend for a mirror effect, except for fluid intelligence and 372 AKI, which showed a U-shape trend. Besides reinforcing its long-established consequence on 373 cognitive function, our results assert the role of the hepatic, musculoskeletal, and pulmonary 374 systems in the 16p11.2 BP4-5 pathophysiology through mechanisms that are independent of the 375 CNV's impact on anthropometric and socio-economic traits.

376 377



Figure 4. 16p11.2 BP4-5 CNV carriers matched-control analyses.

(A-V) Comparison between deletion (DEL) and duplication (DUP) carriers (darker shade) and their respective matched controls (DEL or DUP ctrl; lighter shade) for 22 traits that remained Bonferroni-significant after individually adjusting for body mass index (BMI), height, Townsend deprivation index (TDI), and age at end of education (EA) in Figure 3. For quantitative traits, data are represented as boxplots without outliers and data points for CNV carriers are shown as grey

dots. Sample size of each group is indicated as N. P-values of two-sided t-tests comparing CNV carriers to matched controls are indicated. For binary traits, bars represent disease prevalence in percentage and error bars represent the standard error. Number of cases and total sample size for each group is indicated. P-values of two-sided Fisher tests comparing CNV carriers to matched controls are indicated. "ns" indicates p > 0.05. Traits are colored according to physiological systems. COPD = chronic obstructive pulmonary disease.

378 Finally, we performed sensitivity analyses to validate the robustness of our conclusions. As a 379 negative control, we performed the matched-control analysis for the 24 traits that were 380 significantly associated with 16p11.2 BP4-5 CNVs in our PheWAS but whose association was 381 dependent on adjustment for mediators or that could not be tested in the covariate analysis due 382 to high trait-mediator correlation (Figure S3; Tables S4-5). In line with these associations being 383 secondary consequences to the effect of the CNV on factors on which the matching was 384 performed, only three traits had a nominally significant CNV association, and none survived 385 Bonferroni correction. This strongly contrasts with our main matched-control analysis, where only 386 three traits *lacked* a nominally significant effect: recurrent depression (Figure 4L), anemia (Figure 387 40), and cystatin C (Figure 4U). This absence of results could either be the result of a loss in 388 statistical power resulting from CNV carrier subsampling or by these associations being driven by 389 a combination of factors on which the matching was performed. The former could be exacerbated 390 by the fact that CNV carriers with the more extreme phenotypes were less likely to have 25 391 matched controls in the UKBB. To explore this hypothesis, we compared mean trait value or 392 disease prevalence between the subset of CNV carriers used for the matched-control analysis 393 and the one excluded due to missing data or lack of a sufficient number of matched controls 394 (Figure S4; Tables S4-5). Except for recurrent depression and FVC, all comparisons were non-395 significant ($p \ge 0.05$), indicating that subsampling does not strongly impact our results. For 396 recurrent depression, the only three duplication carriers diagnosed with the disease were not 397 included in the matched-control analysis (p = 0.03; Figure S4L), indicating that the non-significant 398 effect of the duplication on recurrent depression (Figure 4L) is likely caused by subsampling. For 399 FVC, excluded deletion carriers exhibited a more pronounced phenotypic decrease than the ones 400 retained for the matched-control analysis (p = 0.02; Figure S4R), suggesting that an even more 401 extreme difference would have been observed if these individuals had been included in the 402 matched-control analysis (Figure 4R). Conversely, the role of the CNV on anemia risk and cystatin 403 C is likely driven by the effect of the CNV on adiposity and socio-economic status.

404

405 **Discussion**

In this study, we perform a comprehensive PheWAS assessing the relation between 16p11.2 BP45 CNVs and 117 complex traits and diseases in the general population through four dosage

408 mechanisms of action. Our results confirm the extreme pleiotropy of 16p11.2 BP4-5 409 rearrangements, with 46 traits associating with the CNV. In line with the more deleterious nature 410 of the deletion, haploinsufficiency associated with 38 unique traits, while only 10 traits associated 411 with the region's duplication. Further emphasizing how the same genetic region can affect 412 different traits through different dosage mechanisms, we identify traits for which the loss and gain 413 of a copy had an opposite (e.g., BMI or platelet count) or alternatively, a similar (e.g., grip strength 414 or fluid intelligence) consequences on the phenotype. Besides assessing the role of dosage in 415 pleiotropy, we also estimated the fraction of associations that are likely to be secondary to some 416 hallmark features of the CNV and validated through bidirectional MR that mediation is a likely 417 scenario. While height did not mediate any associations, sixteen (61%) of the deletion-driven 418 associations were found to be BMI-dependent, thirteen of which (81%) received support from MR 419 for a scenario wherein the association is consequential to an initial increase in BMI. Conversely, 420 the role of EA and TDI was more subtle, with only five associations showing confounding by these 421 factors. Importantly, some associations were found to be independent of all the tested mediators, 422 suggesting genuine direct pleiotropy of the region on musculoskeletal, hepatic, metabolic, 423 neuropsychiatric, reproductive, hematological, pulmonary, immune, and renal function.

424

425 Our findings have far-reaching consequences for clinical practice and highlight knowledge gaps. 426 First, our results show that increased BMI in deletion carriers drives numerous adult-onset 427 comorbidities. Studies have shown that weight gain in 16p11.2 BP4-5 deletion carriers starts during early childhood, to rapidly progress to obesity^{9,16,45–47}. This emphasizes the importance of 428 429 following pediatric cases by a dedicated team of endocrinologists and nutritionists who can 430 implement a weight control strategy at an early age to attenuate ensuing adult co-morbidities. Second, we show that some other traits are affected independently of the CNV's effect on BMI, 431 432 cognition, and SES. Besides recapitulating well-established hallmark features, such as the CNV's 433 negative impact on cognitive ability or the duplication-specific risk of bipolar disorder or 434 depression, we also link the CNV with milder afflictions of systems that had previously been implicated in clinical cohorts. For instance, increased risk for AKI might be the consequence of 435 436 subclinical structural defects of the kidney that could affect renal function in the long term, 437 paralleling the predisposition of deletion carriers to congenital anomalies of the kidney and urinary 438 tract⁴⁸⁻⁵⁰. Similarly, increased risk for pneumonia might reflect an impaired immune system that is 439 exacerbated into a full-blown immunodeficiency in deletion carriers that also present with a lossof-function variant in CORO1A⁵¹ (MIM: 605000). Other traits that are affected through BMI-440 441 independent mechanisms, such as bone mineral density, platelet counts, pulmonary function, and

442 liver enzymes have not been linked with the CNV in clinical cohorts and future research should 443 establish how often these traits are altered in carriers and which are the molecular mechanisms 444 that mediate this pleiotropy. These could be explored by gene-to-trait mapping strategies such as rare variant gene burden tests^{52,53}, as well as MR⁵⁴ or colocalization⁵⁵ that integrate association 445 446 signals from common SNP-GWAS with transcriptomic and proteomic data to pinpoint genes linked 447 with specific phenotypes. These data could also be leveraged to generate gene-by-trait 448 association matrices whose clustering may reveal groups of traits with shared underlying genetic 449 influences and for which CNV associations are more likely to disappear upon adjustment for one 450 another. Thirdly, our results expose intriguing findings, casting light on questions that remain 451 unanswered by the current study. For instance, the BMI-dependent association of the deletion 452 with type 1 diabetes could be driven by misdiagnosing type 2 diabetes as type 1 due to early-453 onset diabetes following early-onset obesity. We also identify an association between the deletion 454 and decreased creatinine levels. Creatinine levels are typically elevated in patients with renal 455 dysfunction, as is the case for many deletion carriers. We speculate that these results could be the consequences of reduced hepatic function or muscle mass, both of which are present among 456 457 deletion carriers. Similarly, it remains unclear whether elevated levels of ALP - for which levels of 458 specific isoenzymes were not determined in UKBB – reflect hepatic, renal, or skeletal dysfunction. 459 Validation of these hypotheses requires in-depth phenotypic characterization of carriers' medical 460 records but will be crucial to better define the molecular pathophysiology of 16p11.2 BP4-5 CNV 461 carriers and hopefully lead to actionable insights related to the management of the condition's co-462 morbidities.

463

464 Our study is not without limitations. First, by assessing a relatively homogenous cohort, our study 465 likely misses pleiotropic consequences that are only expressed in certain genetic or 466 environmental backgrounds, a phenomenon exacerbated by the relatively small absolute number 467 of CNV carriers which hinders our statistical power. Future studies are needed to confirm trends 468 that we observe at sub-significant level. Second, we decided to focus on only four covariates, 469 which based on the literature, represent strong candidates to mediate indirect pleiotropic 470 consequences of the region's rearrangement. While height and BMI can be measured with 471 relatively high accuracy. EA and TDI only offer rough and imperfect proxies for complex 472 characteristics such as cognitive function and SES, possibly explaining their weaker mediatory 473 role. Other factors that we did not assess might mediate the relation between 16p11.2 BP4-5 474 CNVs and some of the associated traits. Third, the conducted MR analysis comes with its own 475 limitations, namely violation of the exclusion-restriction assumption via correlated pleiotropy,

476 which may have resulted in false positive mediator-to-trait causal effects^{56,57}. Still, if both adjusted 477 and unadjusted regression analyses show a significant CNV effect, we can convincingly suggest 478 that independent pleiotropic mechanisms are at play. Finally, while our study brings us a step 479 closer to understanding the pleiotropy of the region, it fails to provide molecular insights into 480 mechanisms of pleiotropy, for which experimental approaches and leveraging of other mutational 481 classes offer promising avenues.

482

In conclusion, our study provides a framework to start disentangling the complex pleiotropic patterns associated with genomic disorders. For 16p11.2 BP4-5, the latter appears to be a mixture of indirect effects mediated by the impact of the CNV on adiposity and cognition, and direct effects on a broad range of physiological systems. This suggests that independent molecular mechanisms are involved in translating dosage changes into the many co-morbidities linked to the genomic disorder.

489

490 Data & Code availability

491 UK Biobank data are available for registered users and were accessed through the application 492 number 16389. Summary statistics used for Mendelian randomization studies are publicly 493 available, as described in the Methods. All data produced by this study are available in 494 Supplemental Tables. Code will be made available upon publication at: 495 https://github.com/cauwerx/16p11.2 BP4-5 pleiotropy.

496

497 **Author contributions**

498 CA performed all analyses, except for MR analyses conducted by SM; ZK supervised statistical 499 analyses; CA, ZK, and AR interpreted the data; CA generated the figures and drafted the 500 manuscript; ZK and AR made critical revisions; All authors approved the final manuscript.

501

502 Acknowledgments

503 We thank UKBB biobank participants for sharing their data. Computations were performed on the 504 Urblauna server from the University of Lausanne. The study was funded by the Swiss National 505 Science Foundation (31003A_182632, AR; 310030_189147, ZK), Horizon2020 Twinning projects 506 (ePerMed 692145, AR), and the Department of Computational Biology (ZK) and the Center for 507 Integrative Genomics (AR) from the University of Lausanne.

508

509 Declaration of interests

- 510 The authors have no conflicts of interest to declare.
- 511

512 **References**

- Cooper, G.M., Coe, B.P., Girirajan, S., Rosenfeld, J.A., Vu, T.H., Baker, C., Williams, C., Stalker, H., Hamid, R., Hannig, V., et al. (2011). A copy number variation morbidity map of developmental delay. Nat Genet *43*, 838–846.
 10.1038/ng.909.
- Bijlsma, E.K., Gijsbers, A.C.J., Schuurs-Hoeijmakers, J.H.M., Van Haeringen, A., Fransen Van De Putte, D.E., Anderlid, B.-M., Lundin, J., Lapunzina, P., Pé Rez Jurado, L.A., Delle Chiaie, B., et al. (2009). Extending the phenotype of recurrent rearrangements of 16p11.2: Deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet 52, 77–87. 10.1016/j.ejmg.2009.03.006.
- Rosenfeld, J.A., Coppinger, J., Bejjani, B.A., Girirajan, S., Eichler, E.E., Shaffer, L.G., and Ballif, B.C. (2010).
 Speech delays and behavioral problems are the predominant features in individuals with developmental delays and 16p11.2 microdeletions and microduplications. J Neurodev Disord 2, 26–38. 10.1007/S11689-009-9037-4.
- Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-martin, C., Walsh, T., Yamrom, B., Yoon, S., Krasnitz, A.,
 Kendall, J., et al. (2007). Strong Association of De Novo Copy Number Mutations with Autism. Science (1979) *316*,
 445–449. 10.1126/science.1138659.
- Weiss, L.A., Shen, Y., Korn, J.M., Arking, D.E., Miller, D.T., Fossdal, R., Saemundsen, E., Stefansson, H., Ferreira,
 M.A.R., Green, T., et al. (2008). Association between Microdeletion and Microduplication at 16p11.2 and Autism.
 N Engl J Med 358, 667–675. 10.1056/NEJMoa075974.
- 529 6. Kumar, R.A., Karamohamed, S., Sudi, J., Conrad, D.F., Brune, C., Badner, J.A., Gilliam, T.C., Nowak, N.J., Cook,
 530 E.H., Dobyns, W.B., et al. (2008). Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet *17*, 628–638.
 531 10.1093/HMG/DDM376.
- 532 7. Marshall, C.R., Noor, A., Vincent, J.B., Lionel, A.C., Feuk, L., Skaug, J., Shago, M., Moessner, R., Pinto, D., Ren,
 533 Y., et al. (2008). Structural Variation of Chromosomes in Autism Spectrum Disorder. Am J Hum Genet *82*, 477–
 534 488. 10.1016/j.ajhg.2007.12.009.
- 535 8. Jacquemont, S., Reymond, A., Zufferey, F., Harewood, L., Walters, R.G., Kutalik, Z., Martinet, D., Shen, Y.,
 536 Valsesia, A., Beckmann, N.D., et al. (2011). Mirror extreme BMI phenotypes associated with gene dosage at the
 537 chromosome 16p11.2 locus. Nature 478, 97–102. 10.1038/nature10406.
- Walters, R.G., Jacquemont, S., Valsesia, A., De Smith, A.J., Martinet, D., Andersson, J., Falchi, M., Chen, F.,
 Andrieux, J., Lobbens, S., et al. (2010). A new highly penetrant form of obesity due to deletions on chromosome
 16p11.2. Nature 463, 671–675. 10.1038/nature08727.
- Bochukova, E.G., Huang, N., Keogh, J., Henning, E., Purmann, C., Blaszczyk, K., Saeed, S., Hamilton-Shield, J.,
 Clayton-Smith, J., O'Rahilly, S., et al. (2010). Large, rare chromosomal deletions associated with severe early onset obesity. Nature *463*, 666–670. 10.1038/nature08689.
- 544 11. Shinawi, M., Liu, P., Kang, S.H.L., Shen, J., Belmont, J.W., Scott, D.A., Probst, F.J., Craigen, W.J., Graham, B.H.,
 545 Pursley, A., et al. (2010). Recurrent reciprocal 16p11.2 rearrangements associated with global developmental
 546 delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 47, 332–341.
 547 10.1136/JMG.2009.073015.
- 548 12. McCarthy, S.E., Makarov, V., Kirov, G., Addington, A.M., McClellan, J., Yoon, S., Perkins, D.O., Dickel, D.E.,
 549 Kusenda, M., Krastoshevsky, O., et al. (2009). Microduplications of 16p11.2 are associated with schizophrenia.
 550 Nat Genet *41*, 1223–1227. 10.1038/ng.474.
- 13. Mefford, H.C., Muhle, H., Ostertag, P., von Spiczak, S., Buysse, K., Baker, C., Franke, A., Malafosse, A., Genton,
 P., Thomas, P., et al. (2010). Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in
 Idiopathic Generalized and Focal Epilepsies. PLoS Genet 6, e1000962. 10.1371/JOURNAL.PGEN.1000962.
- Walsh, T., McClellan, J.M., McCarthy, S.E., Addington, A.M., Pierce, S.B., Cooper, G.M., Nord, A.S., Kusenda, M.,
 Malhotra, D., Bhandari, A., et al. (2008). Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (1979) *320*, 539–543. 10.1126/science.1155174.
- 15. Hanson, E., Bernier, R., Porche, K., Jackson, F.I., Goin-Kochel, R.P., Green Snyder, L., Snow, A. V, Stevens
 Wallace, A., Campe, K.L., Zhang, Y., et al. (2015). The Cognitive and Behavioral Phenotype of the 16p11.2 Deletion
 in a Clinically Ascertained Population. Biol Psychiatry *77*, 785–793. 10.1016/j.biopsych.2014.04.021.

- 560 16. Zufferey, F., Sherr, E.H., Beckmann, N.D., Hanson, E., Maillard, A.M., Hippolyte, L., Macé, A., Ferrari, C., Kutalik,
 561 Z., Andrieux, J., et al. (2012). A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and
 562 neuropsychiatric disorders. J Med Genet *49*, 660–668. 10.1136/jmedgenet-2012-101203.
- 563 17. D'Angelo, D., Lebon, S., Chen, Q., Martin-Brevet, S., Snyder, L.A.G., Hippolyte, L., Hanson, E., Maillard, A.M.,
 564 Faucett, W.A., Macé, A., et al. (2016). Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and
 565 Medical Comorbidities. JAMA Psychiatry 73, 20–30. 10.1001/JAMAPSYCHIATRY.2015.2123.
- 566 18. Green Snyder, L.A., D'Angelo, D., Chen, Q., Bernier, R., Goin-Kochel, R.P., Wallace, A.S., Gerdts, J., Kanne, S.,
 567 Berry, L., Blaskey, L., et al. (2016). Autism Spectrum Disorder, Developmental and Psychiatric Features in 16p11.2
 568 Duplication. J Autism Dev Disord *46*, 2734–2748. 10.1007/S10803-016-2807-4.
- 19. Niarchou, M., Chawner, S.J.R.A., Doherty, J.L., Maillard, A.M., Jacquemont, S., Chung, W.K., Green-Snyder, L.A.,
 Bernier, R.A., Goin-Kochel, R.P., Hanson, E., et al. (2019). Psychiatric disorders in children with 16p11.2 deletion
 and duplication. Transl Psychiatry 9, 8. 10.1038/s41398-018-0339-8.
- 572 20. Aguirre, M., Rivas, M.A., and Priest, J. (2019). Phenome-wide Burden of Copy-Number Variation in the UK
 573 Biobank. Am J Hum Genet *105*, 373–383. 10.1016/j.ajhg.2019.07.001.
- 574 21. Auwerx, C., Lepamets, M., Sadler, M.C., Patxot, M., Stojanov, M., Baud, D., Mägi, R., Porcu, E., Reymond, A., and
 575 Kutalik, Z. (2022). The individual and global impact of copy-number variants on complex human traits. Am J Hum
 576 Genet *109*, 647–668. 10.1016/j.ajhg.2022.02.010.
- 577 22. Auwerx, C., Jõeloo, M., Sadler, M.C., Tesio, N., Ojavee, S., Clark, C.J., Mägi, R., Esko, T., Metspalu, A., Milani, L.,
 578 et al. (2024). Rare copy-number variants as modulators of common disease susceptibility. Genome Med *16*, 5.
 579 10.1186/s13073-023-01265-5.
- 580 23. Crawford, K., Bracher-Smith, M., Owen, D., Kendall, K.M., Rees, E., Pardiñas, A.F., Einon, M., Escott-Price, V.,
 581 Walters, J.T.R., O'Donovan, M.C., et al. (2019). Medical consequences of pathogenic CNVs in adults: Analysis of
 582 the UK Biobank. J Med Genet 56, 131–138. 10.1136/jmedgenet-2018-105477.
- 583 24. Owen, D., Bracher-Smith, M., Kendall, K.M., Rees, E., Einon, M., Escott-Price, V., Owen, M.J., O'Donovan, M.C.,
 584 and Kirov, G. (2018). Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. BMC
 585 Genomics *19*, 1–9. 10.1186/s12864-018-5292-7.
- 586 25. Macé, A., Tuke, M.A., Deelen, P., Kristiansson, K., Mattsson, H., Nõukas, M., Sapkota, Y., Schick, U., Porcu, E.,
 587 Rüeger, S., et al. (2017). CNV-association meta-analysis in 191,161 European adults reveals new loci associated
 588 with anthropometric traits. Nat Commun *8*, 744. 10.1038/s41467-017-00556-x.
- 589 26. Collins, R.L., Glessner, J.T., Porcu, E., Lepamets, M., Brandon, R., Lauricella, C., Han, L., Morley, T., Niestroj, L.M.,
 590 Ulirsch, J., et al. (2022). A cross-disorder dosage sensitivity map of the human genome. Cell *185*, 3041-3055.e25.
 591 10.1016/j.cell.2022.06.036.
- 592 27. Hujoel, M.L.A., Sherman, M.A., Barton, A.R., Mukamel, R.E., Sankaran, V.G., Terao, C., and Loh, P.-R. (2022).
 593 Influences of rare copy-number variation on human complex traits. Cell *185*, 4233–4248.
 594 10.1016/j.cell.2022.09.028.
- 595 28. Birnbaum, R., Mahjani, B., Loos, R.J.F., and Sharp, A.J. (2022). Clinical Characterization of Copy Number Variants
 596 Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank. JAMA Psychiatry 79, 250–259. 10.1001/JAMAPSYCHIATRY.2021.4080.
- 598 29. Martin, C.L., Wain, K.E., Oetjens, M.T., Tolwinski, K., Palen, E., Hare-Harris, A., Habegger, L., Maxwell, E.K., Reid,
 599 J.G., Walsh, L.K., et al. (2020). Identification of Neuropsychiatric Copy Number Variants in a Health Care System
 600 Population. JAMA Psychiatry 77, 1276–1285. 10.1001/jamapsychiatry.2020.2159.
- Sinnott-Armstrong, N., Tanigawa, Y., Amar, D., Mars, N., Benner, C., Aguirre, M., Venkataraman, G.R., Wainberg,
 M., Ollila, H.M., Kiiskinen, T., et al. (2021). Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat
 Genet *53*, 185–194. 10.1038/s41588-020-00757-z.
- 31. Männik, K., Mägi, R., Macé, A., Cole, B., Guyatt, A.L., Shihab, H.A., Maillard, A.M., Alavere, H., Kolk, A., Reigo, A.,
 et al. (2015). Copy number variations and cognitive phenotypes in unselected populations. JAMA *313*, 2044–2054.
 10.1001/jama.2015.4845.
- 407 32. Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J.,
 408 Langdon, R., et al. (2018). The MR-base platform supports systematic causal inference across the human
 409 phenome. Elife 7. 10.7554/ELIFE.34408.
- 610 33. Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation
 611 PLINK: Rising to the challenge of larger and richer datasets. Gigascience *4*, 1–16. 10.1186/s13742-015-0047-8.

- 612 34. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O.,
 613 O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–
 614 209. 10.1038/s41586-018-0579-z.
- 615 35. Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.A., Hakonarson, H., and Bucan, M. (2007). PennCNV:
 616 An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome
 617 SNP genotyping data. Genome Res *17*, 1665–1674. 10.1101/gr.6861907.
- 618 36. Macé, A., Tuke, M.A., Beckmann, J.S., Lin, L., Jacquemont, S., Weedon, M.N., Reymond, A., and Kutalik, Z.
 619 (2016). New quality measure for SNP array based CNV detection. Bioinformatics *32*, 3298–3305.
 620 10.1093/bioinformatics/btw477.
- 621 37. Karczewski, K.J., Gupta, R., Kanai, M., Lu, W., Tsuo, K., Wang, Y., Walters, R.K., Turley, P., Callier, S., Baya, N.,
 622 et al. (2024). Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and resolution into ancestry-enriched effects. medRxiv. 10.1101/2024.03.13.24303864.
- 624 38. Okbay, A., Wu, Y., Wang, N., Jayashankar, H., Bennett, M., Nehzati, S.M., Sidorenko, J., Kweon, H., Goldman, G.,
 625 Gjorgjieva, T., et al. (2022). Polygenic prediction of educational attainment within and between families from
 626 genome-wide association analyses in 3 million individuals. Nat Genet *54*, 437–449. 10.1038/s41588-022-01016627 z.
- Walter, K., Min, J.L., Huang, J., Crooks, L., Memari, Y., McCarthy, S., Perry, J.R.B., Xu, C., Futema, M., Lawson,
 D., et al. (2015). The UK10K project identifies rare variants in health and disease. Nature 526, 82–90.
 10.1038/nature14962.
- 40. Moix, S., Sadler, M., Kutalik, Z., and Auwerx, C. (2024). Breaking down causes, consequences, and mediating effects of age-related telomere shortening on human health. medRxiv. 10.1101/2024.01.12.24301196.
- 41. Sadler, M.C., Auwerx, C., Lepik, K., Porcu, E., and Kutalik, Z. (2022). Quantifying the role of transcript levels in mediating DNA methylation effects on complex traits and diseases. Nat Commun *13*, 1–14. 10.1038/s41467-022-35196-3.
- 42. Gale, C.R., Hagenaars, S.P., Davies, G., Hill, W.D., Liewald, D.C.M., Cullen, B., Penninx, B.W., Boomsma, D.I.,
 Pell, J., McIntosh, A.M., et al. (2016). Pleiotropy between neuroticism and physical and mental health: findings
 from 108 038 men and women in UK Biobank. Transl Psychiatry 6, e791–e791. 10.1038/tp.2016.56.
- 43. Kendall, K.M., Rees, E., Escott-Price, V., Einon, M., Thomas, R., Hewitt, J., O'Donovan, M.C., Owen, M.J., Walters,
 J.T.R., and Kirov, G. (2017). Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis
 of 152,000 UK Biobank Subjects. Biol Psychiatry *82*, 103–110. 10.1016/j.biopsych.2016.08.014.
- 44. Tyrrell, J., Jones, S.E., Beaumont, R., Astley, C.M., Lovell, R., Yaghootkar, H., Tuke, M., Ruth, K.S., Freathy, R.M.,
 Hirschhorn, J.N., et al. (2016). Height, body mass index, and socioeconomic status: mendelian randomisation
 study in UK Biobank. BMJ 352, i582. 10.1136/bmj.i582.
- 45. Yu, Y., Zhu, H., Miller, D.T., Gusella, J.F., Platt, O.S., Wu, B.-L., and Shen, Y. (2011). Age- and gender-dependent obesity in individuals with 16p11.2 deletion. J Genet Genomics 389, 403–409. 10.1016/j.jgg.2011.08.003.
- 647 46. Gill, R., Chen, Q., D'Angelo, D., and Chung, W.K. (2014). Eating in the absence of hunger but not loss of control behaviors are associated with 16p11.2 deletions. Obesity 22, 2625–2631. 10.1002/OBY.20892.
- 47. Abawi, O., Wahab, R.J., Kleinendorst, L., Blankers, L.A., Brandsma, A.E., Van Rossum, E.F.C., Van Der Voorn, B.,
 Van Haelst, M.M., Gaillard, R., and Van Den Akker, E.L.T. (2023). Genetic Obesity Disorders: Body Mass Index
 Trajectories and Age of Onset of Obesity Compared with Children with Obesity from the General Population. J
 Pediatr 262, 113619. 10.1016/j.jpeds.2023.113619.
- 48. Verbitsky, M., Krithivasan, P., Batourina, E., Khan, A., Graham, S.E., Marasà, M., Kim, H., Lim, T.Y., Weng, P.L.,
 Sánchez-Rodríguez, E., et al. (2021). Copy Number Variant Analysis and Genome-wide Association Study Identify
 Loci with Large Effect for Vesicoureteral Reflux. J Am Soc Nephrol *32*, 805–820. 10.1681/ASN.2020050681.
- 49. Verbitsky, M., Westland, R., Perez, A., Kiryluk, K., Liu, Q., Krithivasan, P., Mitrotti, A., Fasel, D.A., Batourina, E.,
 Sampson, M.G., et al. (2019). The copy number variation landscape of congenital anomalies of the kidney and
 urinary tract. Nat Genet *51*, 117–127. 10.1038/s41588-018-0281-y.
- 50. Yang, N., Wu, N., Dong, S., Zhang, L., Zhao, Y., Chen, W., Du, R., Song, C., Ren, X., Liu, J., et al. (2020). Human and mouse studies establish TBX6 in Mendelian CAKUT and as a potential driver of kidney defects associated with the 16p11.2 microdeletion syndrome. Kidney Int *98*, 1020–1030. 10.1016/j.kint.2020.04.045.
- 51. Shiow, L.R., Paris, K., Akana, M.C., Cyster, J.G., Sorensen, R.U., and Puck, J.M. (2009). Severe combined
 immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a coronin-1A
 mutation and a chromosome 16p11.2 deletion. Clinical immunology : the official journal of the Clinical Immunology
 Society *131*, 24–30. 10.1016/j.clim.2008.11.002.

- 52. Backman, J.D., Li, A.H., Marcketta, A., Sun, D., Mbatchou, J., Kessler, M.D., Benner, C., Liu, D., Locke, A.E.,
 Balasubramanian, S., et al. (2021). Exome sequencing and analysis of 454,787 UK Biobank participants. Nature.
 10.1038/s41586-021-04103-z.
- 53. Karczewski, K.J., Solomonson, M., Chao, K.R., Goodrich, J.K., Tiao, G., Lu, W., Riley-Gillis, B.M., Tsai, E.A., Kim,
 H.I., Zheng, X., et al. (2022). Systematic single-variant and gene-based association testing of thousands of
 phenotypes in 394,841 UK Biobank exomes. Cell genomics 2, 100168. 10.1016/J.XGEN.2022.100168.
- 54. Porcu, E., Rüeger, S., Lepik, K., Agbessi, M., Ahsan, H., Alves, I., Andiappan, A., Arindrarto, W., Awadalla, P.,
 Battle, A., et al. (2019). Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants
 of complex and clinical traits. Nat Commun *10*, 1–12. 10.1038/s41467-019-10936-0.
- 675 55. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and Plagnol, V. (2014).
 676 Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLoS
 677 Genet *10*, e1004383. 10.1371/JOURNAL.PGEN.1004383.
- 678 56. Morrison, J., Knoblauch, N., Marcus, J.H., Stephens, M., and He, X. (2020). Mendelian randomization accounting
 679 for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet *52*, 740–747.
 680 10.1038/s41588-020-0631-4.
- 57. Darrous, L., Mounier, N., and Kutalik, Z. (2021). Simultaneous estimation of bi-directional causal effects and
 heritable confounding from GWAS summary statistics. Nat Commun *12*, 1–15. 10.1038/s41467-021-26970-w.